Urology

Nocturia

Ferring’s antidiuretic compound, MINIRIN® (desmopressin), has completed its clinical development programme for the treatment of nocturia and has recently been approved for this indication in a number of countries worldwide. Many other countries are also considering an approval for this indication.

Nocturia is defined as the night-time urge to void and is a voluntary act of micturition (urination). The cause of nocturia is multifactorial with about 70 per cent of the nocturic population suffering from nocturnal polyuria where urinary production during the night exceeds the bladder's capacity.

Prostate cancer

Ferring's research into the management of prostate cancer has focused on the gonadotropin-releasing hormone (GnRH) receptor. In 1996, a collaboration between scientists from the world-renowned Salk Institute, in San Diego US, Ferring scientists led to the discovery of a new generation of GnRH receptor analogues including FIRMAGON® (degarelix), a potent and selective GnRH receptor blocker. FIRMAGON has been fully developed and approved for treatment of advanced prostate cancer in the US (2008) and in the EU (2009).

This type of drug may also treat a number of other diseases and Ferring is actively investigating other potential indications.

Your name* This field is required Your email address* This field is required

Recipient's email address* This field is required

By using the service, you agree to the following:

Your email address and the recipient's email address will be used for transmission purposes only - to inform the addressee about the sender, or for sending a message in the event of a transmission error. Both email addresses will be deleted from our system after a short period.

Share this page

Urology

The message has been sent